Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab + Pertuzumab in HER2+ Breast Cancer
NCT04929548Phase 4Not yet recruiting
- Sponsor
- Wuhan University
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 4 trial of pyrotinib in breast cancer, sponsored by Wuhan University. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04929548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929548.